Physician profile
Amy R Baker
NPI 1932532934
$14,184.48
in general payments reported to CMS, 2019-2025
73 companies · $1,958 in 2025
The $1,958 reported for 2025 was more than what 92% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,770 · 2022: $4,369 · 2023: $2,813 · 2024: $1,274 · 2025: $1,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,545 · Education: $333 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,545.35 |
| Education | $333.31 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,632.46 | 2021-2025 | Carvykti, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $1,244.98 | 2021-2025 | Calquence, Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $1,077.24 | 2021-2023 | Kisqali, Piqray |
| Daiichi Sankyo INC. | $838.78 | 2021-2025 | Enhertu, Datroway |
| Seagen INC. | $603.81 | 2021-2023 | Adcetris, Tukysa |
| Amgen INC. | $551.20 | 2021-2023 | Lumakras, Blincyto, Evenity |
| Pfizer INC. | $536.88 | 2021-2025 | |
| Incyte Corporation | $504.81 | 2021-2025 | Jakafi, Jakafi, Monjuvi |
| Genzyme Corporation | $482.86 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $438.09 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $431.95 | 2021-2024 | Opdivo |
| Rigel Pharmaceuticals, INC. | $383.41 | 2021-2023 | Rezlidhia, Tavalisse |
| Regeneron Healthcare Solutions, INC. | $325.35 | 2021-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $323.44 | 2021-2025 | Onivyde, Tazverik |
| Celgene Corporation | $308.70 | 2021-2023 | Reblozyl |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.